The Novel Atypical Dopamine Uptake Inhibitor
anergia
depression
dopamine
fatigue
modafinil
motivation
synthesis
transport
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2019
2019
Historique:
received:
15
10
2018
accepted:
27
05
2019
entrez:
19
7
2019
pubmed:
19
7
2019
medline:
19
7
2019
Statut:
epublish
Résumé
Animal studies of effort-based choice behavior are being used to model effort-related motivational dysfunctions in humans. With these procedures, animals are offered a choice between high-effort instrumental actions leading to highly valued reinforcers vs. low effort/low reward options. Several previous studies have shown that dopamine (DA) uptake inhibitors, including GBR12909, lisdexamfetamine, methylphenidate, and PRX-14040, can reverse the effort-related effects of the vesicular monoamine transport blocker tetrabenazine, which inhibits DA storage. Because many drugs that block DA transport act as major stimulants that also release DA, and produce a number of undesirable side effects, there is a need to develop and characterize novel atypical DA transport inhibitors.
Identifiants
pubmed: 31316379
doi: 10.3389/fphar.2019.00682
pmc: PMC6611521
doi:
Types de publication
Journal Article
Langues
eng
Pagination
682Références
Am J Chin Med. 2000;28(1):97-104
pubmed: 10794121
Curr Opin Investig Drugs. 2000 Oct;1(2):241-51
pubmed: 11249581
Psychopharmacology (Berl). 2001 Apr;154(4):375-82
pubmed: 11349390
Psychopharmacology (Berl). 2002 Apr;160(4):371-80
pubmed: 11919664
J Neurochem. 2002 Apr;81(2):292-300
pubmed: 12064476
Int J Neuropsychopharmacol. 2005 Mar;8(1):93-105
pubmed: 15482632
Psychopharmacology (Berl). 2006 May;185(4):451-8
pubmed: 16550389
Biol Psychiatry. 2006 Dec 15;60(12):1350-5
pubmed: 16934768
Mov Disord. 2007 Feb 15;22(3):297-308
pubmed: 17133511
Psychopharmacology (Berl). 2007 Apr;191(3):461-82
pubmed: 17225164
Ann Pharmacother. 2007 Jun;41(6):1005-12
pubmed: 17519297
Neuropsychopharmacology. 2008 Jul;33(8):1966-79
pubmed: 17805307
Biochem Pharmacol. 2008 Jan 1;75(1):2-16
pubmed: 17897630
Expert Rev Neurother. 2007 Oct;7(10):1251-63
pubmed: 17939764
J Neurochem. 2008 Nov;107(4):928-40
pubmed: 18786172
BMC Neurol. 2009 Dec 18;9:62
pubmed: 20021666
Neuroscience. 2010 Apr 14;166(4):1056-67
pubmed: 20096336
Behav Neurosci. 2010 Apr;124(2):179-91
pubmed: 20364878
Mol Neurodegener. 2010 Apr 26;5:18
pubmed: 20420689
Biol Psychiatry. 2011 Feb 1;69(3):201-7
pubmed: 20801429
Am J Geriatr Pharmacother. 2010 Aug;8(4):331-73
pubmed: 20869622
Neuropsychiatr Dis Treat. 2010 Oct 05;6:657-65
pubmed: 20957126
Int Clin Psychopharmacol. 1990 Oct;5(4):237-51
pubmed: 2150527
Cogn Affect Behav Neurosci. 2012 Mar;12(1):74-84
pubmed: 22012275
Dialogues Clin Neurosci. 1999 Dec;1(3):165-74
pubmed: 22034135
PLoS One. 2011;6(10):e25790
pubmed: 22043293
J Neurosci. 2011 Nov 16;31(46):16597-602
pubmed: 22090487
Neuropsychopharmacology. 2012 Sep;37(10):2194-209
pubmed: 22569506
J Abnorm Psychol. 2012 Aug;121(3):553-8
pubmed: 22775583
Neuropharmacology. 2013 Jan;64:490-5
pubmed: 22820554
PLoS One. 2012;7(10):e47934
pubmed: 23110135
Neuron. 2012 Nov 8;76(3):470-85
pubmed: 23141060
Psychopharmacology (Berl). 2013 Sep;229(2):307-21
pubmed: 23612854
Psychopharmacology (Berl). 2013 Oct;229(3):415-34
pubmed: 23934211
Depress Anxiety. 2014 Mar;31(3):250-7
pubmed: 24115209
Psychopharmacology (Berl). 2014 Feb;231(4):727-36
pubmed: 24136220
Compr Psychiatry. 2014 Jan;55(1):1-10
pubmed: 24268564
J Neurosci. 2013 Dec 4;33(49):19120-30
pubmed: 24305809
J Psychopharmacol. 2014 Feb;28(2):118-24
pubmed: 24352716
Neuropsychopharmacology. 2014 Sep;39(10):2441-9
pubmed: 24804846
Biol Psychiatry. 2014 Nov 15;76(10):802-9
pubmed: 24853388
PLoS One. 2014 Jun 17;9(6):e99320
pubmed: 24937131
Int J Neuropsychopharmacol. 2014 Dec;17(12):2045-56
pubmed: 24964269
Psychiatry Res. 2014 Dec 30;220(3):874-82
pubmed: 25262638
Psychopharmacology (Berl). 2015 Apr;232(7):1313-23
pubmed: 25323625
Neuropsychopharmacology. 2015 Mar;40(4):1005-15
pubmed: 25328051
Int J Neuropsychopharmacol. 2014 Oct 31;18(2):null
pubmed: 25575584
Psychopharmacology (Berl). 2015 Jul;232(13):2377-91
pubmed: 25647696
Cortex. 2015 Aug;69:40-6
pubmed: 25967086
Pharmacol Biochem Behav. 2015 Aug;135:217-26
pubmed: 26022661
Neuropsychopharmacology. 2016 Feb;41(3):686-94
pubmed: 26105139
Curr Top Behav Neurosci. 2016;27:231-57
pubmed: 26323245
Neuropharmacology. 2016 Jun;105:630-638
pubmed: 26686391
Psychopharmacology (Berl). 2016 Mar;233(6):949-60
pubmed: 26694811
Neuropsychopharmacology. 2016 Jul;41(8):2147-59
pubmed: 26830960
Behav Processes. 2016 Jun;127:3-17
pubmed: 26899746
Brain. 2016 May;139(Pt 5):1325-47
pubmed: 27189581
Pharmacol Biochem Behav. 2016 Sep;148:84-91
pubmed: 27296079
Neuropharmacology. 2016 Oct;109:270-280
pubmed: 27329556
Psychopharmacology (Berl). 2016 Oct;233(19-20):3575-86
pubmed: 27497935
Eur J Neurosci. 2017 Jan;45(1):167-174
pubmed: 27545285
J Pharmacol Exp Ther. 2016 Dec;359(3):460-470
pubmed: 27733628
J Med Chem. 2016 Dec 8;59(23):10676-10691
pubmed: 27933960
Eur J Neurosci. 2017 Jul;46(1):1682-1688
pubmed: 28543944
Schizophr Bull. 2017 Jul 1;43(4):701-705
pubmed: 28969354
J Neurosci. 2017 Nov 8;37(45):10867-10876
pubmed: 29118216
Front Behav Neurosci. 2017 Nov 27;11:222
pubmed: 29230168
Behav Brain Res. 2018 May 2;343:83-94
pubmed: 29410048
Neuropharmacology. 2018 Sep 15;140:130-138
pubmed: 30053443
Pharmacol Rev. 2018 Oct;70(4):747-762
pubmed: 30209181
Front Behav Neurosci. 2019 Apr 11;13:63
pubmed: 31031603
Pharmacol Biochem Behav. 1998 Mar;59(3):557-66
pubmed: 9512057